Orchestra BioMed Holdings (OBIO) Net Cash Flow Growth (1y) (2022 - 2026)
Orchestra BioMed Holdings (OBIO) Net Cash Flow Growth (1y) (2022 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,140.12 Bn | 66,139.83 Bn | - | -88.82% |
| 2 | Nanobiotix | 1,912.79 Bn | 1,912.73 Bn | - | - |
| 3 | Akari Therapeutics | 1,022.34 Bn | 1,022.34 Bn | - | - |
| 4 | BeOne Medicines | 472.60 Bn | 467.81 Bn | 1.35 Bn | 301.06% |
| 5 | Vertex Pharmaceuticals | 122.34 Bn | 115.09 Bn | 2.59 Bn | 453.08% |
| 6 | Regeneron Pharmaceuticals | 70.14 Bn | 61.39 Bn | 3.31 Bn | -125.22% |
| 7 | Belite Bio | 62.79 Bn | 62.79 Bn | - | - |
| 8 | Argenx Se | 56.19 Bn | 51.00 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.50 Bn | 34.49 Bn | 959.66 Mn | 53.46% |
| 10 | Orchestra BioMed Holdings | 240.22 Mn | 145.82 Mn | 78,000.00 | -61.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -61.59% |
| Dec 31, 2025 | -118.96% |
| Sep 30, 2025 | 1,129.55% |
| Jun 30, 2025 | 3.08% |
| Mar 31, 2025 | 45.92% |
| Dec 31, 2024 | -129.13% |
| Sep 30, 2024 | -29.11% |
| Jun 30, 2024 | 117.02% |
| Mar 31, 2024 | -564.37% |
| Dec 31, 2023 | 114.87% |
| Sep 30, 2023 | 126.75% |
| Jun 30, 2023 | -102.94% |
| Mar 31, 2023 | -105.62% |
| Dec 31, 2022 | -267,668.34% |
| Sep 30, 2022 | -7,694.70% |
| Jun 30, 2022 | 198,454.75% |
| Mar 31, 2022 | 25,492.15% |